Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

84.58 -1.81 (-2.10%)
Delayed Quote Updated: 11:49 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
Via Chartmill
Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗
Via Chartmill
News headline image
Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
Mirum (MIRM) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗
This small biotech could grow much larger with some good news from its pipeline. 
Via The Motley Fool
News headline image
Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharma (MIRM) Earnings Call Transcript ↗
Mirum Pharma (MIRM) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience
NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health,... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗
Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision... 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.